BioVie Inc. (NASDAQ:BIVI – Get Free Report) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,920,000 shares, an increase of 922.9% from the October 15th total of 187,700 shares. Based on an average daily volume of 5,160,000 shares, the short-interest ratio is currently 0.4 days. Approximately 35.0% of the company’s shares are short sold.
Institutional Investors Weigh In On BioVie
A hedge fund recently raised its stake in BioVie stock. Sheaff Brock Investment Advisors LLC lifted its position in shares of BioVie Inc. (NASDAQ:BIVI – Free Report) by 276.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,400 shares of the company’s stock after purchasing an additional 37,762 shares during the quarter. Sheaff Brock Investment Advisors LLC owned about 0.13% of BioVie worth $27,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 4.59% of the company’s stock.
BioVie Price Performance
NASDAQ BIVI opened at $3.41 on Thursday. BioVie has a 1 year low of $1.04 and a 1 year high of $58.20. The business’s 50-day moving average is $2.20 and its 200 day moving average is $1.41.
BioVie Company Profile
BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
Featured Stories
- Five stocks we like better than BioVie
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Insiders Bet Big on These Small Cap Stocks
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Can United States Cellular Ride Higher on Its Spectrum Strategy?
- The Significance of Brokerage Rankings in Stock Selection
- HubSpot’s Growth in CRM: Can It Compete With Salesforce?
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.